2012-11-14 10:03:57 -

Alacris Theranostics GmbH /
Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for 
early stage cancer research 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Berlin,   14th November  2012  -   Alacris  Theranostics  has  entered  into  an
agreement  with GlaxoSmithKline (GSK) to  apply Alacris' proprietary ModCell(TM)
System,  developed  at  the  Max  Planck  Institute  for  Molecular Genetics and
licensed  exclusively to Alacris, for drug  stratification using data from early
stage cancer drug discovery at GSK.

GSK will provide to Alacris pre-clinical biology data from a drug discovery
project in oncology. Alacris will exploit its proprietary   Systems Biology model
to determine the in silico effect of the inhibitor in its "virtual clinical
trial" system. Alacris will then suggest which cancer cell lines as well as
which cancers are more likely to respond to the inhibitor. This will be based on
whole genome and transcriptome data that is integrated in the Alacris' cancer
model ModCell(TM)

About Alacris Theranostics GmbH:

Alacris  Theranostics (www.alacris.de) is a  company based in Berlin specialized
in  developing  new  approaches  in  personalized  medicine  for  cancer patient
diagnosis, treatment and drug stratification. Alacris Theranostics is applying a
systems  biology approach exclusively licensed  as ModCell(TM) to Alacris. Based
on  genome and transcriptome information  obtained by next generation sequencing
and  including  kinetic  pathway  information,  mutation and drug databases, the
systems  biology approach is  providing a "Virtual  Patient" model. The
"Virtual
Patient"   model  can  predict  the  effect  of  drug  treatment  and  optimized
combinatory  treatment providing means for cancer patient stratification and for
personalized medicine approaches. In addition Alacris' "Virtual Clinical
Trials"
system  permits  the  in  silico  analysis  of  drugs, thus identifying specific
patient  groups  or  particular  genetic  profiles  and  diseases  that could be
targeted  by the drug, with the goal  of more efficient and precise treatment of
patients.

Contact:

Alacris Theranostics GmbH
Dr Bodo Lange, CEO

Fabeckstrasse 60-62
D-14195 Berlin
Germany
Phone: +49 30 841 312 01
Email: info@alacris.de

www.alacris.de


MC Services AG
Anne Hennecke, Managing Partner
Phone +49 89 210 228 18
Email: anne.hennecke@mc-services.eu 

Press release (PDF): 
 hugin.info/155582/R/1657734/536257.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Alacris Theranostics GmbH via Thomson Reuters ONE
[HUG#1657734]